Volume 3

Schedule 1—Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

(section 4)

Part 2 – Table 1

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2136	FABIANA IMBRICATA	A, H	
2137	FAGOPYRUM ESCULENTUM	A, H	
2138	FAGUS GRANDIFOLIA	A, H	
2139	FAGUS SYLVATICA	A, H	
2140	FALLOPIA MULTIFLORA	A, H	When for oral use, the medicine requires the following warning statement on the medicine label: - (FALLMUL) 'Warning: Fallopia multiflora may harm the liver in some people. Use under the supervision of a healthcare professional.'
2141	FARNESOL	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2142	FARNESYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as part of a flavour or fragrance proprietary excipient formulation. When used in a flavour, the total flavour proprietary excipient formulation in a medicine must be no more than 5%. When used in a fragrance, the total fragrance proprietary excipient formulation in a medicine must be no more than 1%.
2143	FAST GREEN FCF	E	Permitted for use only as a colour for oral and topical use.
2144	FENCHONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2145	FENCHYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total
			fragrance concentration in a medicine must be no more than 1%.
2146	FENCHYL ALCOHOL	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2147	FENNEL BITTER SEED DRY	A, E, H	When used in oral medicines and the medicine is listed in the

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			Register on or after 1 October 2017 the medicine must have the following statements on the medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended'
			- (PREGNT2) 'Do not use if pregnant or likely to become pregnant (or words to that effect)'
			- (BREASF) 'Do not use while breastfeeding.'
			When used in oral medicines and the medicine is listed in the Register before 1 October 2017 the medicine requires the following statements on the medicine label if supplied after 1 April 2019:
			- (CHILD3) 'Use in children under 12 years is not recommended'
			- (PREGNT2) 'Do not use if pregnant or likely to become pregnant (or words to that effect)'
			- (BREASF) 'Do not use while breastfeeding.'

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2148	FENNEL LEAF	Е	
2149	FENNEL OIL	A, E, H	Methyl chavicol is a mandatory component of fennel oil. When the concentration of methyl chavicol in the medicine is more than 5%, the nominal capacity of the container must be no more than 25mL, a restricted flow insert must be fitted on the container, and the medicine requires the following warning statement on the medicine label: - (CHILD) 'Keep out of reach of children (or words to that effect).' The maximum daily dose must provide no more than 150 mg of fennel oil. When used in oral medicines and the medicine is listed in the Register on or after 1 October 2017 the medicine must have the following statements on the medicine label: - (CHILD3) 'Use in children under 12 years is not recommended.' - (PREGNT2) 'Do not use if

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			pregnant or likely to become pregnant (or words to that effect).'
			- (BREASF) 'Do not use while breastfeeding.'
			When used in oral medicines and the medicine is listed in the Register before 1 October 2017 the medicine requires the following statements on the medicine label if supplied after 1 April 2019:
			- (CHILD3) 'Use in children under 12 years is not recommended.'
			- (PREGNT2) 'Do not use if pregnant or likely to become pregnant (or words to that effect).'
			- (BREASF) 'Do not use while breastfeeding.'
2150	FENNEL SWEET SEED DRY	A, E, H	When used in oral medicines and the medicine is listed in the Register on or after 1 October 2017 the medicine must have the following statements on the medicine label: - (CHILD3) 'Use in children
			under 12 years is not

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			recommended' - (PREGNT2) 'Do not use if pregnant or likely to become pregnant (or words to that effect)' - (BREASF) 'Do not use while breastfeeding.' When used in oral medicines and the medicine is listed in the Register before 1 October 2017 the medicine requires the following statements on the medicine label if supplied after 1 April 2019: - (CHILD3) 'Use in children under 12 years is not recommended' - (PREGNT2) 'Do not use if pregnant or likely to become pregnant (or words to that effect)' - (BREASF) 'Do not use while breastfeeding.'
2151	FENUGREEK	Е	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			flavour concentration in a medicine must be no more than 5%.
2152	FENUGREEK OIL	E	Fenugreek oil is permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2153	FERRIC AMMONIUM CITRATE	A, E, H	When for internal use, iron is a mandatory component of ferric ammonium citrate. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure.
			When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims and the medicine is listed in the Register on or after 1 October 2017 the medicine must have the following statement on the medicine label:
			- (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect). When for internal use except for iron-containing multivitamin/mineral products

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			indicated for general nutritional support that do not make specific iron-deficiency related claims and the medicine is listed in the Register before 1 October 2017 the medicine requires the following statement on the medicine label if supplied after 1 April 2019: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2154	FERRIC CHLORIDE	A, E, H	When for internal use, iron is a mandatory component of ferric chloride. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron.
			In undivided preparations, the primary pack must contain no more than 750 mg of iron

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			(excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the medicine requires the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2155	FERRIC CHLORIDE HEXAHYDRATE	A, E, H	When for internal use, iron is a mandatory component of ferric chloride hexahydrate.
			When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron.
			If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron.
			In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%).
			Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure.
			Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the medicine requires the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2156	FERRIC GLYCEROPHOSPHATE	A, E, H	When for internal use, iron is a mandatory component of ferric glycerophosphate. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the medicine requires the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2157	FERRIC OXIDE	Е	
2158	FERRIC PHOSPHATE	Н	Only for use as an active homoeopathic ingredient.
2159	FERRIC PYROPHOSPHATE	A, H	When for internal use, iron is a mandatory component of ferric pyrophosphate. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			resistant closure. Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the medicine requires the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2160	FERROSOFERRIC OXIDE	E	When used in undivided preparations for internal use and the concentration of iron oxide in the medicine is more than 1%, it is considered part of the total iron content. When used in divided preparations for internal use, the concentration in the medicine must be no more than 10 mg per dosage unit.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2161	FERROSOFERRIC PHOSPHATE	Н	Only for use as an active homoeopathic ingredient.
2162	FERROUS FUMARATE	A, H	When for internal use, iron is a mandatory component of ferrous fumarate. When used as an active ingredient, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5mg of elemental iron per dosage unit and more than 250 milligrams of elemental iron in the total contents of the container are required to have a child

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			resistant closure. Undivided preparations containing more than 250 milligrams of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the medicine requires the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2163	FERROUS GLUCONATE	А, Е, Н	When for internal use, iron is a mandatory component of ferrous gluconate. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron.
			In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%).
			Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure.
			Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure.
			When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the medicine requires the following statement on the medicine label:

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			- (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2164	FERROUS GLUCONATE DIHYDRATE	A, E, H	When for internal use, iron is a mandatory component of ferrous gluconate dihydrate. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron.
			If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron.
			In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%).
			Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			required to have a child resistant closure.
			Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure.
			When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the medicine requires the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that
			effect).
2165	FERROUS IODIDE	Н	Only for use as an active homoeopathic ingredient.
2166	FERROUS LACTATE TRIHYDRATE	A, E, H	When for internal use, iron is a mandatory component of ferrous lactate trihydrate.
			When used as an active ingredient, the medicine must

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			contain a daily dose of no more than 24 mg of iron.
			If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron.
			In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%).
			Divided preparations with a dose of more than 5mg of elemental iron per dosage unit and more than 250 milligrams of elemental iron in the total contents of the container are required to have a child resistant closure.
			Undivided preparations containing more than 250 milligrams of elemental iron in the total contents of the container are required to have a child resistant closure.
			When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			specific iron-deficiency related claims, the medicine requires the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2167	FERROUS PHOSPHATE OCTAHYDRATE	A, E, H	When for internal use, iron is a mandatory component of ferrous phosphate octahydrate. When used as an active ingredient, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			dose of more than 5mg of elemental iron per dosage unit and more than 250 milligrams of elemental iron in the total contents of the container are required to have a child resistant closure.
			Undivided preparations containing more than 250 milligrams of elemental iron in the total contents of the container are required to have a child resistant closure.
			When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the medicine requires the following statement on the medicine label:
			- (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2168	FERROUS PICRATE	Н	Only for use as an active homoeopathic ingredient.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2169	FERROUS SULFATE	A, E, H	When used as an active ingredient, the medicine must contain a daily dose of no more than 24 mg of iron.
			If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron.
			In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%).
			Divided preparations with a dose of more than 5mg of elemental iron per dosage unit and more than 250 milligrams of elemental iron in the total contents of the container are required to have a child resistant closure.
			Undivided preparations containing more than 250 milligrams of elemental iron in the total contents of the container are required to have a child resistant closure.
			When for internal use except for iron-containing multivitamin/mineral products

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			indicated for general nutritional support that do not make specific iron-deficiency related claims, the medicine requires the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2170	FERROUS SULFATE HEPTAHYDRATE	A, E, H	When for internal use, iron is a mandatory component of ferrous sulfate heptahydrate. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			and more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure.
			Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure.
			When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the medicine requires the following statement on the medicine label:
			- (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2171	FERULA ASSA-FOETIDA	A, E, H	
2172	FERULA FOETIDA	A, E, H	
2173	FERULA GALBANIFLUA	A, E, H	
2174	FERULA RUBRICAULIS	A, E, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2175	FERULA SUMBUL	A, H	
2176	FERULIC ACID	Е	Only for use in topical medicines for dermal application.
2177	FESTUCA ELATIOR	A, H	
2178	FEVERFEW HERB DRY	A, H	
2179	FEVERFEW HERB POWDER	A, H	
2180	FICUS CARICA	A, E, H	
2181	FICUS PUMILA	A, H	
2182	FIG	Е	
2183	FIG DRY	A, H	
2184	FILIPENDULA ULMARIA	A, H	Methyl salicylate is a mandatory component of Filipendula ulmaria. Not to be used orally, unless the concentration of methyl salicylate in the medicine is no more than 0.001%. When the concentration of methyl salicylate in the medicine is more than 0.001%, only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			When the concentration of methyl salicylate in a liquid preparation is more than 5%, and the dosage form is other than spray, the medicine requires child resistant packaging.
			When the concentration of methyl salicylate in a liquid preparation is more than 5%, and the dosage form is spray, the medicine does not require child resistant packaging but the delivery device must be engaged into the container in such a way that prevents it from being readily removed, direct suction through the delivery device results in delivery of no more than one dosage unit, and actuation of the spray device is ergonomically difficult for young children to accomplish.
2185	FIR BALSAM ABSOLUTE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			1%.
2186	FIR NEEDLE OIL CANADIAN	A, E	
2187	FIR NEEDLE OIL SIBERIAN	A, E	
2188	FIRMIANA SIMPLEX	A, E, H	
2189	FISH OIL - RICH IN OMEGA-3 ACIDS	A	Only for use in oral medicines.
2190	FLEMINGIA MACROPHYLLA	A, H	
2191	FLOUVE OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2192	FLUORESCEIN SODIUM	E	
2193	FOENICULUM VULGARE	A, E, H	When used in oral medicines and the medicine is listed in the Register on or after 1 October 2017 the medicine must have the following statements on the

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			medicine label:
			- (CHILD3) 'Use in children under 12 years is not recommended'
			- (PREGNT2) 'Do not use if pregnant or likely to become pregnant (or words to that effect)'
			- (BREASF) 'Do not use while breastfeeding.'
			When used in oral medicines and the medicine is listed in the Register before 1 October 2017 the medicine requires the following statements on the medicine label if supplied after 1 April 2019:
			- (CHILD3) 'Use in children under 12 years is not recommended'
			- (PREGNT2) 'Do not use if pregnant or likely to become pregnant (or words to that effect)'
			- (BREASF) 'Do not use while breastfeeding.'
			When the plant preparation is oil or distillate, methyl chavicol is a mandatory component and the maximum daily dose must provide no

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			more than 150 mg of the plant preparation.
			When the plant preparation is oil or distillate and the concentration of methyl chavicol in the medicine is more than 5%, the nominal capacity of the container must be no more than 25mL, a restricted flow insert must fitted on the container, and the medicine requires the following warning statement on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect).
2194	FOLIC ACID	A	When for internal use, the maximum recommended daily dose must be no more than 500 micrograms of folic acid. When folic acid, folinic acid, levomefolate salts and/or their derivatives are used in combination, the medicine must provide no more than a total of 500 micrograms of folic acid, folinic acid, levomefolate salts and/or their derivatives in total per daily

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			dose. When used in preparations indicated for reducing the risk of having a child with spina bifida/neural tube defects: a) the maximum daily dose must provide 400 – 500 micrograms of folic acid; and b) the following statement must be included on the label: - (NEUR) 'Warning: Do not exceed the stated dose except on medical advice. If you have had a baby with a neural tube defect/spina bifida - seek specific medical advice (or words to that effect)'.
2195	FOOD ORANGE 6	E	Permitted for use only as a colour for oral and topical use.
2196	FOOD ORANGE 7	E	Permitted for use only as a colour for oral and topical use.
2197	FOOD RED 13	E	Permitted for use only as a colour for topical use.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2198	FORMALDEHYDE/MELAMINE/T OSYLAMIDE COPOLYMER	Е	Only for use in topical medicines for dermal application. The concentration in the medicine must be no more than 10%.
2199	FORMIC ACID	Н	Only for use as an active homoeopathic ingredient.
2200	FORSYTHIA SUSPENSA	A, H	
2201	FORTIFIED WINE	E	Ethanol is a mandatory component of fortified wine. When the concentration of ethanol in the medicine is more than 3%, the medicine requires the following warning statement on the medicine label: - (ETHAN) 'Contains ethanol or contains alcohol'.
2202	FRACTIONATED COCONUT OIL	Е	
2203	FRACTIONATED PALM KERNEL OIL	A, E	When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply with an uncompounded

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			substance monograph of the British Pharmacopoeia, as in force or existing from time to time.
2204	FRAGARIA CHILOENSIS	A, E, H	
2205	FRAGARIA VESCA	A, E, H	
2206	FRAGARIA VIRGINIANA	A, E, H	
2207	FRAGARIA X ANANASSA	A, E, H	
2208	FRANGULA BARK DRY	A, H	Glucofrangulins calculated as glucofrangulin A is a mandatory component of Frangula bark dry. When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label: - (CHILD3) 'Use in children under 12 years is not recommended'; - (LAX2) 'Prolonged use may cause serious bowel problems'; and - (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' [or words to that effect].
			When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:
			- (LAX1) 'Drink plenty of water' [or words to that effect].
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and
			- (LAX4) 'This product may have laxative effect'.
			When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the
			medicine requires the following warning statements

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			on the medicine label: - (CHILD3) 'Use in children under 12 years is not recommended'; - (LAX1) 'Drink plenty of water' [or words to that effect]; and - (LAX2) 'Prolonged use may cause serious bowel problems'.
2209	FRANGULA BARK POWDER	A, H	Glucofrangulins calculated as glucofrangulin A is a mandatory component of Frangula bark powder. When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label: - (CHILD3) 'Use in children under 12 years is not recommended'; - (LAX2) 'Prolonged use may cause serious bowel problems'; and - (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product [or words to that effect]'.
			When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:
			- (LAX1) 'Drink plenty of water [or words to that effect]'.
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and
			- (LAX4) 'This product may have laxative effect'.
			When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the
			medicine requires the following warning statements

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			on the medicine label: - (CHILD3) 'Use in children under 12 years is not recommended'; - (LAX1) 'Drink plenty of water [or words to that effect]'; and - (LAX2) 'Prolonged use may cause serious bowel problems'.
2210	FRANGULA PURSHIANA	A, H	When for oral use, hydroxyanthracene derivatives calculated as cascaroside A is a mandatory component of Frangula purshiana. When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label: - (CHILD3) 'Use in children under 12 years is not recommended'; - (LAX2) 'Prolonged use may cause serious bowel problems'; and - (LAX3) 'Do not use when abdominal pain, nausea or

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' [or words to that effect].
			When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:
			- (LAX1) 'Drink plenty of water' [or words to that effect].
			When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
			- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and
			- (LAX4) 'This product may have laxative effect'.
			When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the
			medicine requires the following warning statements

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			on the medicine label: - (CHILD3) 'Use in children under 12 years is not recommended'; - (LAX1) 'Drink plenty of water' [or words to that effect]; and - (LAX2) 'Prolonged use may cause serious bowel problems'.
2211	FRAXINUS AMERICANA	A, H	
2212	FRAXINUS CHINENSIS SUBSP. RHYNCHOPHYLLA	A, H	
2213	FRAXINUS EXCELSIOR	А, Н	The components Nuzhenide and secoiridoid glucoside GL3 are only available when the plant part is seed.
2214	FRAXINUS ORNUS	A, H	
2215	FRITILLARIA CIRRHOSA	А, Н	
2216	FRITILLARIA THUNDBERGII	A, H	
2217	FRITILLARIA VERTICILLATA	A, H	
2218	FRUCTOOLIGOSACCHARIDES	A, E	
2219	FRUCTOSE	A, E, H	
2220	FUCUS VESICULOSUS	A, E, H	Iodine is a mandatory

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			component of Fucus vesiculosus.
			Only for external use when the concentration of available iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less.
			Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.
2221	FUMARIA OFFICINALIS	A, E, H	
2221			
2222	FUMARIC ACID	E, H	Only for use as an active homoeopathic or excipient ingredient.
2223	FUMITORY HERB DRY	А, Н	
2224	FUMITORY HERB POWDER	А, Н	
2225	FURAMINTON	Е	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total
			flavour concentration in a medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			5%.
2226	FURFURAL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2227	FURFURYL ACETATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2228	FURFURYL ALCOHOL	Е	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			5%.
2229	FURFURYL MERCAPTAN	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2230	FUSEL OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2231	GALBANUM OIL	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			medicine must be no more 1%.
2232	GALBANUM PHENOL	Е	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2233	GALBANUM RESIN	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2234	GALBANUM RESINOID	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			medicine must be no more 1%.
2235	GALEGA OFFICINALIS	A, H	
2236	GALEOPSIS SEGETUM	A, H	
2237	GALIUM APARINE	A, H	
2238	GALIUM ODORATUM	A, H	When used as an active ingredient coumarin is a mandatory component of Galium odoratum and the concentration of coumarin in the medicine must be no more than 0.001%.
2239	GALIUM PALUSTRE	A, H	
2240	GALIUM VERUM	A, H	
2241	GALL STONE	Н	Only for use as an active homoeopathic ingredient.
2242	GALPHIMIA GLAUCA	A, H	
2243	GAMMA-4-DIMETHYL-3- CYCLOHEXENE-1-PROPANOL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			1%.
2244	GAMMA-BUTYROLACTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2245	GAMMA-CYCLODEXTRIN	Е	
2246	GAMMA-DECALACTONE	E	Permitted for use only: (a) in topical medicines for dermal application; and (b) in oral medicines in combination with other permitted ingredients as part of a flavour proprietary excipient formulation. When used in a flavour, the total flavour proprietary excipient formulation in a medicine must be no more than 5%.
2247	GAMMA-DODECALACTONE	Е	Permitted for use only in combination with other permitted ingredients as a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2248	GAMMA-HEPTALACTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2249	GAMMA-HEXALACTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			fragrance concentration in a medicine must be no more 1%.
2250	GAMMA-IONONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2251	GAMMA-LINOLEIC ACID	Е	Only for use in topical medicines for dermal application.
2252	GAMMA-LINOLENIC ACID	Е	
2253	GAMMA-N-METHYL IONONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			fragrance concentration in a medicine must be no more 1%.
2254	GAMMA-NONALACTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2255	GAMMA-OCTALACTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2256	GAMMA-TERPINENE	Е	Permitted for use only in combination with other permitted ingredients as a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2257	GAMMA-TOCOPHEROL	Е	
2258	GAMMA-UNDECALACTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2259	GAMMA-VALEROLACTONE	Е	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			5%.
2260	GANODERMA LUCIDUM	A, E, H	
2261	GARCINIA GUMMI-GUTTA	A	Only for use in oral medicines. Must be obtained from the rind of the fruit only. Must not contain any directions for use for children or pregnant or lactating women.
2262	GARCINIA QUAESITA	A, H	
2263	GARDEN BEAN	Е	
2264	GARDENIA JASMINOIDES	A, E	
2265	GARDENIA TAHITENSIS FLOWER EXTRACT	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 0.002%
2266	GARLIC BULB DRY	A, E, H	
2267	GARLIC BULB FRESH	A, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2268	GARLIC BULB POWDER	A, E, H	
2269	GARLIC CLOVE POWDER	A, H	
2270	GARLIC OIL	A, E, H	
2271	GASTRODIA ELATA	A, H	
2272	GAULTHERIA PROCUMBENS	A, E, H	Methyl salicylate is a mandatory component of Gaultheria procumbens. Not to be used orally, unless the concentration of methyl salicylate in the medicine is no more than 0.001%. When the concentration of methyl salicylate in the medicine is more than 0.001%, only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin. When the concentration of methyl salicylate in a liquid preparation is more than 5%, and the dosage form is other than spray, the medicine requires child resistant packaging. When the concentration of methyl salicylate in a liquid preparation is more than 5%, and the dosage form is spray, the medicine does not require

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			child resistant packaging but the delivery device must be engaged into the container in such a way that prevents it from being readily removed, direct suction through the delivery device results in delivery of no more than one dosage unit, and actuation of the spray device is ergonomically difficult for young children to accomplish.
2273	GELATIN	A, E	
2274	GELIDIUM AMANSII	A, H	Iodine is a mandatory component of Gelidium amansii. Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less. Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2275	GELLAN GUM	E	
2276	GELSEMIUM DRY	A, H	The concentration of Gelsemium dry in the medicine must be no more than 1 mg/Kg or 1 mg/L or 0.0001%.
2277	GELSEMIUM POWDER	A, H	
2278	GELSEMIUM SEMPERVIRENS	A, H	The concentration of equivalent dry Gelsemium sempervirens in the product must be no more than 1mg/Kg or 1mg/L or 0.0001%.
2279	GENET ABSOLUTE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2280	GENTIAN DRY	A, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2281	GENTIAN POWDER	A, H	
2282	GENTIANA LUTEA	A, E, H	
2283	GENTIANA MACROPHYLLA	A, H	
2284	GENTIANA RHODANTHA	A, H	
2285	GENTIANA SCABRA	A, H	
2286	GENTIANELLA AMARELLA	A, H	
2287	GERANIAL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2288	GERANIC ACID	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2289	GERANIOL	Е	Permitted for use only: (a) in topical medicines for

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			dermal application; and (b) in oral medicines in combination with other permitted ingredients as part of a flavour proprietary excipient formulation. When used in a flavour, the total flavour proprietary excipient formulation in a medicine must be no more than 5%.
2290	GERANIUM	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2291	GERANIUM MACULATUM	A, E, H	
2292	GERANIUM OIL	A, E, H	
2293	GERANIUM OIL SAPONIFIED	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			1%.
2294	GERANIUM OIL TERPENELESS	Е	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2295	GERANIUM ROBERTIANUM	A, E, H	
2296	GERANIUM ROSE OIL	Е	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2297	GERANIUM SIBIRICUM	A, E, H	
2298	GERANYL ACETATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2299	GERANYL ACETONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2300	GERANYL BUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2301	GERANYL CROTONATE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2302	GERANYL ETHYL ETHER	E	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2303	GERANYL FORMATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2304	GERANYL ISOBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2305	GERANYL ISOVALERATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2306	GERANYL NITRILE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			1%.
2307	GERANYL PROPIONATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2308	GERANYL TIGLATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2309	GEUM RIVALE	A, H	
2310	GEUM URBANUM	A, H	
2311	GHATTI GUM	A, E, H	
2312	GIGARTINA MAMILLOSA	A, H	Iodine is a mandatory component of Gigartina

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			mamillosa. Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less. Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.
2313	GINGER DRY	A, E, H	
2314	GINGER OIL	A, E, H	
2315	GINGER OLEORESIN	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in the medicine must be no more than 5%.
2316	GINGER POWDER	A, E, H	
2317	GINKGO BILOBA	A, E, H	The Ginkgo biloba leaf extract used in the manufacture of this medicine must comply with the requirement of Identification

Ingredient Name		
	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
		Test B of the monograph Powdered Ginkgo Extract in the United States Pharmacopeia 32 - National Formulary 27 (USP32-NF27), as in force or existing from time to time. This condition does not apply to powdered or dried leaf.
GLACIAL ACETIC ACID	E, H	The concentration in the medicine must be no more than 1.5%.
GLECHOMA HEDERACEA	A, H	
GLECHOMA LONGITUBA	A, H	
GLEDITSIA AUSTRALIS	A, H	
GLEDITSIA SINENSIS	A, H	
GLEHNIA LITTORALIS	A, H	
GLORIOSA SUPERBA	А, Н	Colchicine is a mandatory component of Gloriosa superba and must be declared in the application. The concentration of colchicine in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.
	GLECHOMA HEDERACEA GLECHOMA LONGITUBA GLEDITSIA AUSTRALIS GLEDITSIA SINENSIS GLEHNIA LITTORALIS	GLACIAL ACETIC ACID E, H GLECHOMA HEDERACEA A, H GLECHOMA LONGITUBA A, H GLEDITSIA AUSTRALIS A, H GLEDITSIA SINENSIS A, H GLEHNIA LITTORALIS A, H

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2325	GLUCOMANNAN	Е	Only for use when the dosage form is other than tablet.
2326	GLUCONOLACTONE	Е	
2327	GLUCOSAMINE HYDROCHLORIDE	A, E	When derived from seafood, the medicine requires the following warning statement on the medicine label: - (SFOOD) 'Derived from seafood'.
2328	GLUCOSAMINE SULFATE	A	When derived from seafood, the medicine requires the following warning statement on the medicine label: - (SFOOD) 'Derived from seafood'.
2329	GLUCOSAMINE SULFATE POTASSIUM CHLORIDE	A	Potassium chloride is a mandatory component of glucosamine sulfate potassium chloride. When derived from seafood, the medicine requires the following warning statement on the medicine label: - (SFOOD) 'Derived from seafood'.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			When for oral use, the medicine requires the following warning statement on the medicine label: - (POTAS) 'Contains [amount of potassium in milligrams] mg of potassium. If you have kidney disease or are taking heart or blood pressure medicines - consult your doctor or pharmacist before use. Keep out of reach of children.'
2330	GLUCOSAMINE SULFATE SODIUM CHLORIDE	A	When derived from seafood, the medicine requires the following warning statement on the medicine label: - (SFOOD) 'Derived from seafood'.
2331	GLUCOSE	A, E, H	When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label: - (SUGARS) 'Contains [insert

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			name of sugar]' if medicine contains one sugar OR 'Contains sugars' (or words to that effect) if medicine contains two or more sugars. If one of the sugars is lactose then the medicine also requires the following warning statement on the medicine label: - (LACT) 'Contains lactose' (or words to that effect).
2332	GLUCOSE GLUTAMATE	E	Only for use in topical medicines for dermal application.
2333	GLUCOSE MONOHYDRATE	A, E, H	When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose monohydrate, honey, invert sugar, lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label: - (SUGARS) 'Contains [insert name of sugar]' if medicine contains one sugar OR

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			'Contains sugars' (or words to that effect) if medicine contains two or more sugars. If one of the sugars is lactose then the medicine also requires the following warning statement on the medicine label: - (LACT) 'Contains lactose' (or words to that effect).
2334	GLUCOSYLRUTIN	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.1%.
2335	GLUTAMIC ACID	A, E	Only for use in topical medicines for dermal application.
2336	GLUTAMIC ACID HYDROCHLORIDE	A, E, H	
2337	GLUTAMINE	A, E, H	
2338	GLUTARAL	Е	Permitted for use only in combination with other

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2339	GLUTATHIONE	A, E	When used as an active ingredient, glutathione can only be used in medicines with an oral route of administration and must be indicated for use in adults only and not in pregnant or lactating women. The medicine requires the following warning statement on the medicine label: - (PREGNT) 'Not recommended for use by pregnant and lactating women' (or words to that effect) - (ADULT) 'Adults only' (or words to that effect).
2340	GLUTEN-FREE WHEAT STARCH	Е	
2341	GLYCERETH-26	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			The concentration in the medicine must be no more than 7%.
2342	GLYCEROL	A, E	When used as an active ingredient, it is only for use in topical medicines for dermal application.
2343	GLYCEROL ESTER OF PARTIALLY HYDROGENATED GUM ROSIN	E	Only for use when the dosage form is 'chewing gum'. Must comply with: a) the Glycerol Ester of Partially Hydrogenated Gum Rosin monograph in the Food Chemicals Codex published by the United States Pharmacopeial Convention, as in force or existing from time to time; and b) the requirements for residual solvents and catalysts in the British Pharmacopoeia or the United States Pharmacopeia-National Formulary, as in force or existing from time to time.
2344	GLYCERYL BEHENATE	E	Behenic acid is a mandatory component of glyceryl behenate.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			When for oral ingestion, the maximum recommended daily dose must not provide more than 383.5 milligrams of behenic acid. In medicines for topical use, the concentration of glyceryl behenate must be no more than 5%.
2345	GLYCERYL CAPRYLATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 1%.
2346	GLYCERYL DIISOSTEARATE	Е	For use in topical medicines for dermal application.
2347	GLYCERYL DILAURATE	E	Only for use in topical medicines for dermal application.
2348	GLYCERYL DIOLEATE	Е	Only for use in topical medicines for dermal application.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2349	GLYCERYL DISTEARATE	Е	Only for use in topical medicines for dermal application.
2350	GLYCERYL GLUCOSIDE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 5%.
2351	GLYCERYL ISOSTEARATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 5.5%.
2352	GLYCERYL LAURATE	E	Only for use in topical medicines for dermal application.
2353	GLYCERYL LINOLEATE	Е	Only for use in topical medicines for dermal

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			application.
2354	GLYCERYL LINOLENATE	E	Only for use in topical medicines for dermal application.
2355	GLYCERYL MONOOLEATE	E	
2356	GLYCERYL MONOSTEARATE	E	
2357	GLYCERYL MYRISTATE	E	Only for use in topical medicines for dermal application.
2358	GLYCERYL OLEATE CITRATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 4% of the formulation.
2359	GLYCERYL PALMITO- STEARATE	E	
2360	GLYCERYL POLYACRYLATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			for use in the eye. The concentration in the medicine must be no more than 0.15%.
2361	GLYCERYL POLYMETHACRYLATE	E	Only for use in topical medicines for dermal application.
2362	GLYCERYL RICINOLEATE	Е	Only for use in topical medicines for dermal application.
2363	GLYCERYL ROSINATE	E	Only for use when the dosage form is 'chewing gum'. Must comply with: a) the Glycerol Ester of Gum Rosin monograph in the Food Chemicals Codex published by the United States Pharmacopeial Convention, as in force or existing from time to time; and b) the requirements for residual solvents and catalysts in the British Pharmacopeia or the United States Pharmacopeia National Formulary, as in force or existing from time to time.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2364	GLYCERYL SORBITAN OLEOSTEARATE	Е	Only for use in topical medicines for dermal application.
2365	GLYCERYL STARCH	E	Only for use in topical medicines for dermal application. The concentration in the medicine must be no more than 4%. The residual levels of epichlorohydrin are to be kept below the level of detection.
2366	GLYCERYL STEARATE CITRATE	Е	Only for use in topical medicines for dermal application. The concentration in the medicine must be no more than 5%.
2367	GLYCERYL TRIACETYL HYDROXYSTEARATE	E	Only for use in topical medicines for dermal application. The concentration in the medicine must be no more than 6%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2368	GLYCERYL TRIACETYL RICINOLEATE	Е	Only for use in topical medicines for dermal
2369	GLYCERYL TRINITRATE	Н	Only for use as an active homoeopathic ingredient.
2370	GLYCERYL UNDECYLENATE	E	Only for use in topical medicines for dermal application and not to be
			included in medicines intended for use in the eye or on damaged skin. The concentration of glyceryl undecylenate in a medicine must be no more than 3%.
2371	GLYCINE	A, E	
2372	GLYCINE MAX	A, E, H	
2373	GLYCOGEN	E	Only for use in topical medicines for dermal application.
2374	GLYCOL DISTEARATE	E	Only for use in topical medicines for dermal application.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2375	GLYCOLIC ACID	E	Only for use in topical medicines for dermal application. Sponsors should consider the impact of excipients on the sensitivity of the skin to sunlight and should ensure the finished product is safe for its intended purpose. When present as an excipient in sunscreens, the concentration in the medicine must be no more than 5%. When used as an excipient ingredient in other medicines the concentration in the medicines the concentration in the medicine must be no more than 20%. If the concentration is more than 5% but no more than 20%, the pH of the medicine must be 3.5 or greater.
2376	GLYCYRRHIZA GLABRA	A, E, H	
2377	GLYCYRRHIZA SPECIES	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			flavour concentration in a medicine must be no more than 5%.
2378	GLYCYRRHIZA URALENSIS	A, E, H	
2379	GLYCYRRHIZINIC ACID	Е	
2380	GNAPHALIUM AFFINE	A, H	
2381	GNAPHALIUM POLYCEPHALUM	А, Н	
2382	GNAPHALIUM ULIGINOSUM	A, H	
2383	GOAT	Н	Only for use as an active homoeopathic ingredient.
2384	GOAT MILK	E	If the product is for oral ingestion and contains lactose, then the medicine requires the following warning statement on the medicine label: - (LACT) 'Contains lactose' (or words to that effect).
2385	GOLD	Е, Н	Only for use as an active homoeopathic or excipient ingredient.
2386	GOLD CHLORIDE	Н	Only for use as an active

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			homoeopathic ingredient.
2387	GOLDEN ROD HERB DRY	A, E, H	
2388	GOLDEN SEAL ROOT DRY	A, H	
2389	GOLDEN SEAL ROOT POWDER	A, H	
2390	GOLDEN SYRUP	E	Sucrose is a mandatory component of Golden syrup when the route of administration of the medicine is oral or sublingual. When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label: - (SUGARS) 'Contains [insert name of sugar]' if medicine contains one sugar OR 'Contains sugars' (or words to that effect) if medicine contains two or more sugars. If one of the sugars is lactose then the medicine also requires the following warning statement on the medicine

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			label: - (LACT) 'Contains lactose' (or words to that effect).
2391	GOMPHRENA GLOBOSA	A, H	
2392	GOOSEBERRY	Е	
2393	GOSSYPIUM HERBACEUM	A, E, H	
2394	GRAPE	E	
2395	GRAPE SEED OIL	Е	
2396	GRAPE WINE RED	E	Ethanol is a mandatory component of Grape wine red. When the concentration of ethanol in the medicine is more than 3%, the medicine requires the following warning statement on the medicine label: - (ETHAN) 'Contains ethanol' or 'contains alcohol'
2397	GRAPE WINE SHERRY	E	Ethanol is a mandatory component of Grape wine sherry. When the concentration of ethanol in the medicine is more than 3%, the medicine requires the following warning

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			statement on the medicine label: - (ETHAN) 'Contains ethanol' or 'contains alcohol'
2398	GRAPE WINE WHITE	E	Ethanol is a mandatory component of Grape wine white. When the concentration of ethanol in the medicine is more than 3%, the medicine requires the following warning statement on the medicine label: - (ETHAN) 'Contains ethanol' or 'contains alcohol'
2399	GRAPEFRUIT	Е	
2400	GRAPEFRUIT OIL	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2401	GRAPEFRUIT OIL COLDPRESSED	A, E, H	
2402	GRAPEFRUIT OIL CONCENTRATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2403	GRAPEFRUIT OIL TERPENELESS	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2404	GRAPEFRUIT OIL TERPENES AND TERPENOIDS	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			fragrance concentration in a medicine must be no more 1%.
2405	GRAPHITE	Н	Only for use as an active homoeopathic ingredient.
2406	GRATIOLA LINIFOLIA	A, H	
2407	GREATER NETTLE HERB DRY	A, H	
2408	GREATER NETTLE HERB POWDER	A, H	
2409	GREATER NETTLE ROOT DRY	A, H	
2410	GREATER NETTLE ROOT POWDER	A, H	
2411	GREEN LIPPED MUSSEL	A	
2412	GREEN LIPPED MUSSEL DRIED	A	
2413	GREEN LIPPED MUSSEL OIL	A	
2414	GREEN S	E	Only for use as a colour in topical and oral medicines.
2415	GRIFOLA FRONDOSA	A	When the route of administration is oral or sublingual, the medicine requires the following warning statement on the medicine label:

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			-(WARF) 'Do not take while on warfarin therapy without medical advice.'
2416	GRINDELIA CAMPORUM	A, H	
2417	GRINDELIA ROBUSTA	A, H	
2418	GRISALVA	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2419	GROUND IVY HERB DRY	A, H	
2420	GROUND IVY HERB POWDER	A, H	
2421	GUAIAC WOOD OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2422	GUAIACOL	E	Permitted for use only in
			combination with other permitted ingredients as a flavour.
			If used in a flavour the total flavour concentration in the medicine must be no more than 5%.
2423	GUAIACUM OFFICINALE	A, E, H	
2424	GUAIACUM RESIN	A, E, H	
2425	GUAIACUM SANCTUM	A, H	
2426	GUAIACWOOD ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2427	GUAIENE	E	Permitted for use only in combination with other permitted ingredients as a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2428	GUAIYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2429	GUANINE	E	Only for use as an excipient in topical medicines for dermal application.
2430	GUANOSINE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no more than 0.01% in the medicine.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2431	GUAR GALACTOMANNAN	A	When for oral use: (a) the maximum daily dose must provide no more than 25 g of guar galactomannan; (b) the medicine requires the following dosage instructions: - (FIBRE) 'The dose of fibre should be increased gradually. Fluid intake should be increased with an increasing dose of fibre.' (or words to that effect) (c) when the dosage form is a powder preparation, the medicine requires the following dosage instructions: - (DNTPOW) 'Do not take powder alone. Mix with food or fluid.' (or words to that effect).
2432	GUAR GUM	A, E, H	
2433	GUAR HYDROXYPROPYLTRIMONIUM CHLORIDE	Е	Only for use as an excipient in topical medicines for dermal application.
2434	GUAREA RUSBYI	А, Н	
2435	GUAVA	Е	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2436	GURJUN BALSAM	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2437	GYMNADENIA NIGRA	A	
2438	GYMNEMA SYLVESTRE	A, H	
2439	GYMNOCLADUS DIOICA	A, H	
2440	GYNOSTEMMA PENTAPHYLLUM	A	The herbal substance must be derived from the aerial parts of the vine only (stem, leaves, fruit).
2441	GYNURA JAPONICA	A, H	
2442	HAHNEMANN'S SOLUBLE MERCURY	Н	Only for use as an active homoeopathic ingredient.
2443	HALIBUT-LIVER OIL	A, E	Colecalciferol and Vitamin A are mandatory components of Halibut-liver oil.
			When for internal use, the maximum recommended daily dose must be no more than 25

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			micrograms of Vitamin D. When for use in topical medicines, the concentration of Vitamin A in the medicine must be no more than 1%. When for internal use, the maximum daily dose must be no more than 3000 micrograms of Retinol Equivalents. When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label: - (VITA2) 'WARNING: If you are pregnant - or considering becoming pregnant - do not take Vitamin A supplements without consulting your doctor or pharmacist [or words to that effect].' NOTE: Position this warning at the beginning of the directions for use. - (VITA4) 'WARNING - When taken in excess of 3000 micrograms retinol equivalents - Vitamin A can cause birth defects.' NOTE: Position this

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			directions for use. - (VITA3) 'The recommended daily amount of Vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.'
2444	HAMAMELIS LEAF DRY	A, H	
2445	HAMAMELIS LEAF POWDER	A, H	
2446	HAMAMELIS VIRGINIANA	A, E, H	
2447	HAMAMELIS WATER	A, E, H	
2448	HANDROANTHUS HEPTAPHYLLUS	A, H	
2449	HANDROANTHUS IMPETIGINOSUS	A, E, H	
2450	HARD FAT	E	
2451	HARD PARAFFIN	E	
2452	HARICOT BEAN	E	
2453	HARPAGOPHYTUM PROCUMBENS	A, E, H	
2454	HARUNGANA MADAGASCARIENSIS	A, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2455	HAZEL NUT	Е	
2456	HAZEL NUT OIL	Е	
2457	HEAVY KAOLIN	Е	
2458	HEAVY MAGNESIUM OXIDE	A, E, H	
2459	HECTORITE	Е	Only for use in topical medicines for dermal application.
2460	HEDEOMA PULEGIOIDES	A	
2461	HEDERA HELIX	A, H	Emetine is a mandatory component of Hedera helix. The concentration of emetine in the medicine must be no more than 0.2%.
2462	HEDTA	Е	Only for use as an excipient in topical medicines for dermal application.
2463	HEKLA LAVA	H	Only for use as an active homoeopathic ingredient.
2464	HELESTRALIS	E	Permitted for use only in combination with other permitted ingredients as a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2465	HELIANTHEMUM NUMMULARIUM	A, H	
2466	HELIANTHUS ANNUUS	A, E, H	
2467	HELIANTHUS TUBEROSUS	A, H	
2468	HELICHRYSUM ANGUSTIFOLIUM	A, E, H	
2469	HELICHRYSUM ARENARIUM	A, H	
2470	HELIOTROPYL ACETATE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2471	HELLEBORUS NIGER	А, Н	The maximum recommended daily dose must be no more than 1 mg of the equivalent dry herbal material.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2472	HELLEBORUS VIRIDIS	A, H	The maximum recommended daily dose must be no more than 1mg of the equivalent dry herbal material.
2473	HELONIAS RHIZOME DRY	A, H	
2474	HELONIAS RHIZOME POWDER	A, H	
2475	HEMIDESMUS INDICUS	A, E, H	
2476	HEPTANAL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2477	HEPTANAL DIMETHYL ACETAL	Е	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2478	HEPTANOIC ACID	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total
2479	HEPTENAL	E	fragrance concentration in a medicine must be no more 1%. Permitted for use only in
			combination with other permitted ingredients as a flavour. If used in a flavour the total
2400	WINDOW A OPERATOR		flavour concentration in a medicine must be no more than 5%.
2480	HEPTYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2481	HEPTYL BUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2482	HEPTYL UNDECYLENATE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye or on damaged skin. The concentration of the medicine must be no more than 25%.
2483	HERACLEUM HEMSLEYANUM	A, H	
2484	HERNIARIA GLABRA	A, H	
2485	HESPERIDIN	A, E	
2486	HEX-3-ENYL ACETATE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			medicine must be no more than 1%.
2487	HEXAHYDRO-4,7- METHANOINDEN-6-YL PIVALATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2488	HEXAMETHYLINDANOPYRAN	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2489	HEXAN-1-OL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2490	HEXANE	E	The concentration of the medicine must be no more than 0.029%. When used for a route of administration other than topical, the residual solvent limit for Hexane is 2.9 mg per recommended daily dose.
2491	HEXANOATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2492	HEXANOIC ACID	Е	Permitted for use only in combination with other

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2493	HEXASODIUM FYTATE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye or on damaged skin. The concentration of Hexasodium fytate in the medicine must be no more than 1.0 %.
2494	HEXENAL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2495	HEXYL 2-METHYLBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2496	HEXYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2497	HEXYL BUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			medicine must be no more 1%.
2498	HEXYL CAPROATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2499	HEXYL FORMATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2500	HEXYL ISOBUTYRATE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2501	HEXYL ISOVALERATE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2502	HEXYL LAURATE	E	Only for use as an excipient in topical medicines for dermal application.
2503	HEXYL NICOTINATE	E	
2504	HEXYL SALICYLATE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a
			medicine must be no more than 1%.
2505	HEXYL TIGLATE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			1%.
2506	HEXYLDECANOL	E	Only for use as an excipient in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration of the medicine must be no more than 3%.
2507	HEXYLENE GLYCOL	Е	Only for use as an excipient in topical medicines for dermal application.
2508	HIBISCUS ESCULENTUS	A, H	
2509	HIBISCUS MUTABILIS	A, H	
2510	HIBISCUS ROSA-SINENSIS	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2511	HIBISCUS SABDARIFFA	A, E, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2512	HIERACIUM PILOSELLA	A, H	
2513	HIGH AMYLOSE MAIZE STARCH	A, E, H	
2514	HIGH CHROMIUM YEAST	A, E	Chromium is a mandatory component of high chromium yeast. The maximum recommended daily dose must not provide more than 50 micrograms of chromium from organic chromium sources. High chromium yeast is considered to be an organic form of chromium.
2515	HIGH FRUCTOSE MAIZE SYRUP	Е	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2516	HIGH MOLYBDENUM YEAST	A, E	Molybdenum is a mandatory component of high molybdenum yeast. The maximum daily dose of molybdenum from high molybdenum yeast must be no

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			more than 62.5 micrograms.
2517	HIGH SELENIUM YEAST	A	When for oral or sublingual use, selenium is a mandatory component of high selenium yeast. Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose. When for oral use, the medicine requires the following warning statement on the medicine label: - (SELE) 'This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.'
2518	HIMATANTHUS LANCIFOLIUS	A, E, H	
2519	HIPPOPHAE RHAMNOIDES	A, E, H	
2520	HIRSCHFELDIA INCANA	А, Н	Allyl isothiocyanate is a mandatory component of Hirschfeldia incana when the plant part is seed. The concentration of allyl isothiocyanate from all

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			ingredients in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.
2521	HISTAMINE DIHYDROCHLORIDE	Н	Only for use as an active homoeopathic ingredient.
2522	HISTIDINE	A	
2523	HISTIDINE HYDROCHLORIDE	A, E, H	
2524	HO LEAF OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2525	HO WOOD OIL	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2526	HOLCUS LANATUS	A, H	
2527	HOLY THISTLE HERB DRY	A, H	
2528	HOLY THISTLE HERB POWDER	A, H	
2529	HOMALOMENA OCCULTA	A, H	
2530	HOMOSALATE	A, E	For use as an active ingredient only in sunscreens for dermal application. For use as an excipient only in topical medicines for dermal application. Not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 15%. When used in primary sunscreen products and listed in the Register on or after 1 January 2018, the medicine must have the following statements on the medicine label:

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and - (SUNPRO) 'Wear protective
			clothing - hats and eyewear when exposed to the sun' (or words to this effect).
			When used in primary sunscreen products and listed in the Register before 1 January 2018, the medicine requires the following statements on the medicine label if supplied after 1 July 2019:
			- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and
			- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
2531	HONEY	A, E	When the route of administration is oral, the medicine requires the following warning statement on the medicine label:
			- (BABY2) 'Not suitable for infants under the age of twelve

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			months' (or words to that effect). When the medicine is for oral
			ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label:
			- (SUGARS) 'Contains [insert name of sugar]' if medicine contains one sugar OR 'Contains sugars' (or words to that effect) if medicine contains two or more sugars.
			If one of the sugars is lactose then the medicine also requires the following warning statement on the medicine label:
			- (LACT) 'Contains lactose' (or words to that effect).
2532	HONEY BEE	Н	Only for use as an active homoeopathic ingredient.
2533	HONEY EXTRACT	E	Not to be included in

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			medicines intended for use in the eye.
			The concentration in the medicine must be no more than 1%.
			When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label: - (SUGARS) 'Contains [insert name of sugar]' if medicine contains one sugar OR 'Contains sugars' (or words to that effect) if medicine contains two or more sugars.
2534	HONEY POWDER	E	Permitted for use only in combination with other permitted ingredients as a flavour.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2535	HOP STROBILE DRY	A, H	
2536	HOP STROBILE POWDER	A, H	
2537	HOPS OIL	A, E, H	
2538	HORDEUM DISTICHON	A, E, H	Gluten is a mandatory component when the plant part is seed, and must be declared in the application when the route of administration is other than topical and mucosal. When the route of administration is other than topical or mucosal, the medicine requires the following warning statement on the medicine label: - (GLUTEN) 'Contains [insert name of ingredient]' or words to that effect.
2539	HORDEUM VULGARE	A, E, H	Gluten is a mandatory component when the plant part is seed, and must be declared in the application when the route of administration is other than topical and mucosal. When the route of administration is other than topical or mucosal, the medicine requires the

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			following warning statement on the medicine label: - (GLUTEN) 'Contains [insert name of ingredient]' or words to that effect.
2540	HOREHOUND EXTRACT	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2541	HORSE RADISH	E, H	Volatile oil components (of Armoracia rusticana) is a mandatory component of Horse radish. The maximum recommended daily dose must be no more than 20 mg of volatile oil components (of Armoracia rusticana).
2542	HOTTONIA PALUSTRIS	A, H	
2543	HOUTTUYNIA CORDATA	A, H	
2544	HOVENIA DULCIS	A, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2545	HUMULUS LUPULUS	A, E, H	
2546	HYALURONIC ACID	Е	Only for use as an excipient in topical medicines for dermal application.
2547	HYDNOCARPUS ANTHELMINTICA	A, H	When the medicine is for other than topical use and the plant part is seed, the maximum recommended daily dose must be no more than 1 mg of the equivalent dry seed.
2548	HYDRANGEA ARBORESCENS	A, H	
2549	HYDRANGEA PANICULATA	A, H	
2550	HYDRASTIS CANADENSIS	A, E, H	
2551	HYDRATED SILICA	Е	Only for use when the route of administration is other than inhalation.
2552	HYDROCHLORIC ACID	E	The concentration of the medicine must be no more than 0.5%.
2553	HYDROCOTYLE UMBELLATA	A, H	
2554	HYDROFLUORIC ACID	Н	Only for use as an active homoeopathic ingredient.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2555	HYDROGEN CYANIDE	Н	Only for use as an active homoeopathic ingredient.
2556	HYDROGEN PEROXIDE	A, E	When used as the active ingredient, it is only for use in topical medicines for dermal application. The concentration of hydrogen peroxide in the medicine must be no more than 3%. When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time.
2557	HYDROGENATED BUTYLENE/ETHYLENE/STYREN E COPOLYMER	Е	Only for use in topical medicines for dermal application. The combined concentration of hydrogenated butylene/ethylene/stryene copolymer and hydrogenated ethylene/propylene/styrene copolymer in the medicine

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			must be no more than 9%.
2558	HYDROGENATED C6-14 OLEFIN POLYMERS	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 7%.
2559	HYDROGENATED CASTOR OIL	Е	
2560	HYDROGENATED COCO- GLYCERIDES	Е	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 3%.
2561	HYDROGENATED COCONUT OIL	Е	
2562	HYDROGENATED COTTONSEED OIL	Е	
2563	HYDROGENATED DIMER DILINOLEYL/DIMETHYLCARBO NATE COPOLYMER	Е	Only for use in topical medicines for dermal application and not to be included in topical medicines

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			intended for use in the eye. The concentration in the medicine must be no more than 4% in the product.
2564	HYDROGENATED ETHYLENE/PROPYLENE/STYRE NE COPOLYMER	E	The combined concentration of hydrogenated ethylene/propylene/styrene copolymer must be no more than 9%.
2565	HYDROGENATED LANOLIN	E	
2566	HYDROGENATED LECITHIN	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 5%.
2567	HYDROGENATED PALM GLYCERIDES	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 1.6%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2568	HYDROGENATED PALM GLYCERIDES CITRATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin. The concentration in the medicine must be no more than 0.01%.
2569	HYDROGENATED PALM KERNEL OIL	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 1.2%.
2570	HYDROGENATED PALM OIL	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 2%. Polycyclic aromatic hydrocarbons must be kept below the level of detection.

Column 2	Column 3	Column 4
Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
HYDROGENATED POLYDECENE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
HYDROGENATED POLYISOBUTENE	E	Only for use in topical medicines for dermal application.
HYDROGENATED SOYA OIL	E	
HYDROGENATED TALLOW GLYCERIDE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 3%.
HYDROGENATED VEGETABLE OIL	E	
HYDROLIAC	Е	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a
	HYDROGENATED POLYDECENE HYDROGENATED POLYISOBUTENE HYDROGENATED SOYA OIL HYDROGENATED TALLOW GLYCERIDE HYDROGENATED VEGETABLE OIL	Ingredient Name Purpose of the ingredient in the medicine HYDROGENATED POLYDECENE E HYDROGENATED POLYISOBUTENE E HYDROGENATED SOYA OIL E HYDROGENATED TALLOW GLYCERIDE HYDROGENATED TALLOW E GLYCERIDE HYDROGENATED VEGETABLE OIL

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			medicine must be no more than 5%.
2577	HYDROLYSED ADANSONIA DIGITATA LEAF POLYSACCHARIDES	Е	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 0.01%
2578	HYDROLYSED ALGIN	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 0.02%
2579	HYDROLYSED CEREAL SOLIDS	Е	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2580	HYDROLYSED COLLAGEN	A, E	
2581	HYDROLYSED ELASTIN	E	Only for use in topical medicines for dermal application.
2582	HYDROLYSED GELATIN	A, E	
2583	HYDROLYSED GLYCOSAMINOGLYCANS	Е	Only for use in topical medicines for dermal application.
2584	HYDROLYSED JOJOBA ESTERS	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 5%.
2585	HYDROLYSED KERATIN	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 5%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2586	HYDROLYSED MAIZE STARCH	Е	
2587	HYDROLYSED MILK PROTEIN	Е	
2588	HYDROLYSED RICE	A, E, H	
2589	HYDROLYSED RICE PROTEIN	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 0.125%.
2590	HYDROLYSED SOY PROTEIN	E	Only for use in topical medicines for dermal application not to be included in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 0.5%.
2591	HYDROLYSED VEGETABLE PROTEIN	Е	
2592	HYDROLYSED WHEAT PROTEIN	Е	When the route of administration is other than topical or mucosal, the medicine requires the following warning statement

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			on the medicine label: - (GLUTEN) 'Contains [insert name of ingredient]' or words to that effect.
2593	HYDROLYSED WHEAT PROTEIN/PVP CROSSPOLYMER	Е	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 1.2%.
2594	HYDROLYSED YEAST PROTEIN	Е	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 0.3%.
2595	HYDROQUINONE DIMETHYL ETHER	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2596	HYDROUS WOOL FAT	A, E	When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time.
2597	HYDROXOCOBALAMIN	A	
2598	HYDROXYACETOPHENONE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 1%.
2599	HYDROXYAPATITE	A, E	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2600	HYDROXYCITRATE COMPLEX	A	Hydroxycitrate complex must contain one or more of the three salts (calcium, sodium or potassium hydroxycitrate) of hydroxycitric acid.
2601	HYDROXYCITRIC ACID	A	
2602	HYDROXYCITRONELLAL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2603	HYDROXYCITRONELLAL DIMETHYL ACETAL	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2604	HYDROXYCITRONELLAL- METHYLANTHRANILATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a
2605	HYDROXYCITRONELLOL	E	medicine must be no more 1%. Permitted for use only in
2003	ITIDROATCITRONELEOL	E	combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2606	HYDROXYETHYL CETEARAMIDOPROPYLDIMONI UM CHLORIDE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 0.1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2607	HYDROXYETHYL UREA	Е	Only for use in topical
			medicines for dermal application and not to be included in topical medicines intended for use in the eye.
			The concentration must be no more than 1%.
2608	HYDROXYLATED LANOLIN	E	
2609	HYDROXYLATED MILK GLYCERIDES	Е	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye.
			The concentration must be no more than 0.1%.
2610	HYDROXYLYSINE	A, E	
2611	HYDROXYMETHYLCELLULOSE	Е	
2612	HYDROXYOCTACOSANYL HYDROXYSTEARATE	Е	Only for use in topical medicines for dermal application.
2612	HVDDOVVDALMITOVI	Г	Only for use is torical
2613	HYDROXYPALMITOYL SPHINGANINE	Е	Only for use in topical medicines for dermal application and not to be included in topical medicines

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			intended for use in the eye or on damaged skin.
			The concentration must be no more than 0.1%.
2614	HYDROXYPROLINE	A, E	
2615	HYDROXYPROPYL DISTARCH PHOSPHATE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no more than 4%.
2616	HYDROXYPROPYL STARCH	E	
2617	HYDROXYPROPYLBETADEX	Е	Only for use in topical medicines for dermal application.
2618	HYDROXYSTEARIC ACID	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no more than 9%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2619	HYETELLOSE	Е	
2620	HYLOCEREUS LEMAIREI	Е	Permitted for use only as a colour for oral and topical use.
2621	HYLOCEREUS UNDATUS	A, H	
2622	HYMETELLOSE	Е	
2623	HYOSCYAMUS LEAF DRY	A, H	Alkaloids calculated as hyoscyamine and hyoscine are mandatory components of Hyoscamus leaf dry. The concentration of alkaloids calculated as hyoscyamine in the medicine must be no more than 300 micrograms/Kg or 300 micrograms/L or 0.00003%. The concentration of hyoscine in the medicine must be no more than than 300 micrograms/kg or 300 micrograms/kg or 300 micrograms/L or 0.00003%.
2624	HYOSCYAMUS LEAF POWDER	A, H	Alkaloids calculated as hyoscyamine and hyoscine are mandatory components of Hyoscamus leaf powder. The concentration of alkaloids calculated as hyoscyamine in the medicine must be no more than 300 micrograms/Kg or

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			300 micrograms/L or 0.00003%. The concentration of hyoscine in the medicine must be no more than 300 micrograms/kg or 300 micrograms/L or 0.00003%.
2625	HYOSCYAMUS NIGER	A, H	Alkaloids calculated as hyoscyamine and hyoscine are mandatory components of Hyoscyamus niger. The concentration of hyoscyamine in the medicine must be no more than 3 micrograms/kg or 3 micrograms/L or 0.3%. The concentration of hyoscine in the medicine must be no more than 300 micrograms/kg or 300 micrograms/L or 0.00003%.
2626	HYPERICUM ASCYRON	A, H	
2627	HYPERICUM JAPONICUM	A, H	
2628	HYPERICUM PERFORATUM	A, E, H	When used for oral ingestion, the medicine requires the following warning statement on the medicine label: - (STJOHN) 'St John's Wort

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			affects the way many prescription medicines work - including oral contraceptives. Consult your doctor.'
2629	HYPROLOSE	E	
2630	HYPROMELLOSE	E	
2631	HYPROMELLOSE PHTHALATE	Е	
2632	HYPTIS SUAVEOLENS	A, H	
2633	HYSSOPUS OFFICINALIS	A, E, H	
2634	IBERIS AMARA	A, H	
2635	ICHTHAMMOL	Н	Only for use as an active homoeopathic ingredient.
2636	ILEX AQUIFOLIUM	A, H	
2637	ILEX CHINENSIS	A, H	
2638	ILEX PARAGUARIENSIS	A, E, H	Caffeine is a mandatory component of Ilex paraguariensis. When the route of administration is oral or sublingual and the medicine provides a maximum recommended daily dose of more than 1 mg but no more than 10 mg of caffeine in the medicine requires the

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			following warning statement on the medicine label: - (CAFFR) 'The recommended dose of this medicine provides small amounts of caffeine.' When the route of administration is oral or sublingual and the medicine provides a maximum recommended daily dose of more than 10 mg of caffeine in the medicine requires the following warning statement on the medicine label: - (CAFF) 'Contains caffeine [state quantity per dosage unit or per mL or per gram of product]'.
2639	ILEX ROTUNDA	A, H	
2640	ILEX VERTICILLATA	A, H	
2641	ILLICIUM VERUM	A, H	When the plant preparation is oil or distillate, the nominal capacity of the container must be no more than 50 millilitres. When the concentration of Illicium verum oil or distillate in the preparation is greater than 50%, a restricted flow insert must be fitted on the container and the medicine

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			must include the following warning statement on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect).
2642	IMIDUREA	E	Only for use in topical medicines for dermal application. The medicine requires the following warning statement on the medicine label: - (IMIDUR) 'Contains imidurea [or words to that effect]'.
2643	IMMORTELLE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2644	IMMORTELLE OIL	Е	Permitted for use only in combination with other

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			permitted ingredients as a flavour.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2645	IMPATIENS	Е	Permitted for use only in combination with other permitted ingredients as a flavour.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2646	IMPATIENS BALSAMINA	A, H	
2647	IMPATIENS GLANDULIFERA	A, H	
2648	IMPERATA CYLINDRICA	A, E, H	
2649	INDIGO CARMINE	Е	Permitted for use only as a colour for oral and topical use.
2650	INDIGO CARMINE ALUMINIUM LAKE	E	Permitted for use only as a colour for oral and topical use.
2651	INDIGOFERA TINCTORIA	A, H	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2652	INDISAN	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2653	INDOLE	E, H	Only for use as an active homoeopathic or excipient ingredient.
			The maximum recommended daily dose must contain no more than 75 mg indole.
2654	INDOLENE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2655	INDUSTRIAL METHYLATED SPIRIT	E	
2656	INOSITOL	A, E	

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2657	INULA BRITANNICA	A, H	
2658	INULA HELENIUM	A, E, H	
2659	INULA RACEMOSA	A, H	
2660	INULIN	A, E	
2661	INULIN LAURYL CARBAMATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin. The concentration in the medicine must be no more than 1.2%.
2662	INVERT SUGAR	E	When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100 mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label: - (SUGARS) 'Contains [insert name of sugar]' if medicine contains one sugar OR 'Contains sugars' (or words to that effect) if medicine contains two or more sugars.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			If one of the sugars is lactose then the medicine also requires the following warning statement on the medicine label: - (LACT) 'Contains lactose' (or words to that effect).
2663	INVERT SYRUP	E	Glucose is a mandatory component of Invert syrup when the route of administration is oral or sublingual. When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100 mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label: - (SUGARS) 'Contains [insert name of sugar]' if medicine contains one sugar OR 'Contains sugars' (or words to that effect) if medicine contains two or more sugars. If one of the sugars is lactose then the medicine also requires the following warning

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			statement on the medicine label:
			- (LACT) 'Contains lactose' (or words to that effect).
2664	IODINE	Н	Only for use as an active homoeopathic ingredient.
			Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less.
			Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.
2665	IODOPROPYNYL BUTYLCARBAMATE	Е	For use as an excipient ingredient in topical medicines only.
			The concentration in aqueous medicines must be no more than 10%.
2666	IONONE	Е	Permitted for use only:
			(a) in topical medicines for

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			dermal application; and (b) in oral medicines in combination with other permitted ingredients as part of a flavour proprietary excipient formulation. When used in a flavour, the total flavour proprietary excipient formulation in a medicine must be no more than 5%.
2667	IOPAMIDOL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2668	IPECACUANHA DRY	A, H	Emetine is a mandatory component of Ipecacuanha Dry. The concentration of emetine in the medicine must be no more than 0.2%.
2669	IPECACUANHA POWDER	A, H	Emetine is a mandatory component of Ipecacuanha

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			Powder. The concentration of emetine in the medicine must be no more than 0.2%.
2670	IPECACUANHA PREPARED	А, Н	Emetine is a mandatory component of Ipecacuanha Prepared. The concentration of emetine in the medicine must be no more than 0.2%.
2671	IPECACUANHA ROOT LIQUID EXTRACT	А, Н	Emetine is a mandatory component of Ipecacuanha root liquid extract. The concentration of emetine in the medicine must be no more than 0.2%.
2672	IPOMOEA BATATAS	A, H	
2673	IPOMOEA JALAPA	A, H	
2674	IRIDOPHYCUS FLACCIDUM	А, Н	Iodine is a mandatory component of Iridophycus flaccidum. Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			more than 2.5%. Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.
2675	IRIS DOMESTICA	A, H	
2676	IRIS FLORENTINA	A, H	
2677	IRIS GERMANICA	A, H	
2678	IRIS PALLIDA	A, H	
2679	IRIS TENAX	Н	
2680	IRIS VERSICOLOR	A, H	
2681	IRON	A, H	Only for use in oral medicines. When used as an active ingredient, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			(excluding iron oxides when present as an excipient at a quantity of no more than1%). Divided preparations with a dose of more than 5mg of elemental iron per dosage unit and more than 250 milligrams of elemental iron in the total contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250 milligrams of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims and the medicine is listed in the Register on or after 1 October 2017 the medicine must have the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that
			effect). When for internal use except

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims and the medicine is listed in the Register before 1 October 2017 the medicine requires the following statement on the medicine label if supplied after 1 April 2019: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2682	IRON (II) BISGLYCINE SULFATE TRIHYDRATE	A	Only for use in oral medicines. Iron is a mandatory component of iron (II) bisglycine sulfate trihydrate. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure.
			When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims and the medicine is listed in the Register on or after 1 October 2017 the medicine must have the following statement on the medicine label:
			- (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect). When for internal use except
			for iron-containing multivitamin/mineral products

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			indicated for general nutritional support that do not make specific iron-deficiency related claims and the medicine is listed in the Register before 1 October 2017 the medicine requires the following statement on the medicine label if supplied after 1 April 2019: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2683	IRON (II) GLYCINATE	A	Only for use in oral medicines. Iron is a mandatory component of iron (II) glycinate. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%).
			Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure.
			When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims and the medicine is listed in the Register on or after 1 October 2017 the medicine must have the following statement on the medicine label:
			- (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
			When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			claims and the medicine is listed in the Register before 1 October 2017 the medicine requires the following statement on the medicine label if supplied after 1 April 2019: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2684	IRON (III) GLYCINATE	A	Only for use in oral medicines. Iron is a mandatory component of iron (III) glycinate. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure.
			When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims and the medicine is listed in the Register on or after 1 October 2017 the medicine must have the following statement on the medicine label:
			- (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect). When for internal use except for iron-containing multivitamin/mineral products

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			indicated for general nutritional support that do not make specific iron-deficiency related claims and the medicine is listed in the Register before 1 October 2017 the medicine requires the following statement on the medicine label if supplied after 1 April 2019: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2685	IRON AMINO ACID CHELATE	A, H	Only for use in oral medicines. When used internally, iron is a mandatory component of iron amino acid chelate. The concentration of iron in iron amino acid chelate must be no more than 25%. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron.
			If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			primary pack must contain no more than 750 mg of iron.
			In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%).
			Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure.
			Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure.
			When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims and the medicine is listed in the Register on or after 1 October 2017 the medicine must have the following statement on the medicine label:

Column 2	Column 3	Column 4
Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
		- (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
		When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims and the medicine is listed in the Register before 1 October 2017 the medicine requires the following statement on the medicine label if supplied after 1 April 2019: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
IRON OXIDE BLACK	E	Permitted for use only as a colour for oral and topical use. When used in undivided preparations for internal use and the concentration of iron oxide in the medicine is more than 1%, it is considered part of the total iron content. When used in divided
	Ingredient Name	Ingredient Name Purpose of the ingredient in the medicine

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			the concentration in the medicine must be no more than 10 mg per dosage unit.
2687	IRON OXIDE RED	E	Permitted for use only as a colour for oral and topical use. When used in undivided preparations for internal use and the concentration of iron oxide in the medicine is more than 1%, it is considered part of the total iron content. When used in divided preparations for internal use, the concentration in the medicine must be no more than 10 mg per dosage unit.
2688	IRON OXIDE YELLOW	E	Permitted for use only as a colour for oral and topical use. When used in undivided preparations for internal use and the concentration of iron oxide in the medicine is more than 1%, it is considered part of the total iron content. When used in divided preparations for internal use, the concentration in the medicine must be no more than 10 mg per dosage unit.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2689	IRON PHOSPHATE	A, E, H	When used internally, iron is a mandatory component of iron phosphate and must be declared.
			When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron.
			If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron.
			In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%).
			Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure.
			Undivided preparations containing more than 250 mg of elemental iron in the total

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			contents of the container are required to have a child resistant closure.
			When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims and the medicine is listed in the Register on or after 1 October 2017 the medicine must have the following statement on the medicine label:
			- (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
			When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims and the medicine is listed in the Register before 1 October 2017 the medicine requires the following statement on the medicine label if supplied after 1 April 2019:
			- (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			effect).
2690	IRONE	Е	
2691	IRVINGIA GABONENSIS SEED TRIGLYCERIDES	Е	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no more than 0.375%.
2692	ISATIS TINCTORIA	A, H	
2693	ISOAMBRETTOLIDE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2694	ISOAMYL 2-METHYLBUTYRATE	Е	Permitted for use only in combination with other permitted ingredients as a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2695	ISOAMYL ACETATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2696	ISOAMYL ALCOHOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2697	ISOAMYL BENZOATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2400			
2698	ISOAMYL BUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2699	ISOAMYL CAPRYLATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2700	ISOAMYL CINNAMATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2701	ISOAMYL CITRONELLYL KETONE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2702	ISOAMYL FORMATE	E	Permitted for use only in combination with other

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2703	ISOAMYL HEXANOATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total
2704	ISOAMYL ISOBUTYRATE	E	fragrance concentration in a medicine must be no more 1%. Permitted for use only in
			combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2705	ISOAMYL ISOVALERATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2706	ISOAMYL LAURATE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no more than 12%.
2707	ISOAMYL METHOXYCINNAMATE	A	Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye. The concentration in the

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			medicine must be no more than 10%.
			When used in primary sunscreen products and listed in the Register on or after 1 January 2018, the medicine must have the following statements on the medicine label:
			- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and
			- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
			When used in primary sunscreen products and listed in the Register before 1 January 2018, the medicine requires the following statements on the medicine label if supplied after 1 July 2019:
			- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and
			- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2708	ISOAMYL PHENYLACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2709	ISOAMYL PHENYLETHYL ETHER	E	Permitted for use only in combination with other permitted ingredients as part of a fragrance proprietary excipient formulation. The total fragrance proprietary excipient formulation in a medicine must be no more than 1%.
2710	ISOAMYL PROPIONATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2711	ISOAMYL SALICYLATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2712	ISOBERGAMIATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2713	ISOBORNEOL	E	Permitted for use only in combination with other permitted ingredients as a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2714	ISOBORNYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2715	ISOBORNYL CYCLOHEXANOL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2716	ISOBUTANE	Е	Only for use in topical medicines for dermal application.
2717	ISOBUTYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2718	ISOBUTYL ALCOHOL	E	The residual solvent limit for Isobutyl alcohol is 50mg per recommended daily dose. The concentration of isobutyl alcohol must be no more than 0.5% of the formulation.
2719	ISOBUTYL BENZOATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used as a flavour the total

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			flavour concentration in a medicine must be no more than 5%.
2720	ISOBUTYL BENZYL CARBINOL	Е	Permitted for use only in combination with other permitted ingredients as a flavour.
			If used as a flavour the total flavour concentration in a medicine must be no more than 5%.
2721	ISOBUTYL BUTYRATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2722	ISOBUTYL CAPROATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2723	ISOBUTYL CINNAMATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2724	ISOBUTYL FORMATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2725	ISOBUTYL HYDROXYBENZOATE	E	Only for use in topical medicines for dermal application. Medicines containing hydroxybenzoates require the following warning statement on the medicine label: - (TOTBNZ) 'Contains hydroxybenzoates' (or words to this effect) if the medicine contains more than one

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			hydroxybenzoate source OR 'Contains [insert the approved name of hydroxybenzoate used]' (or words to this effect) if product contains one hydroxybenzoate source.
2726	ISOBUTYL ISOBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2727	ISOBUTYL ISOVALERATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2728	ISOBUTYL PHENYLACETATE	Е	Permitted for use only in combination with other

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2729	ISOBUTYL PROPIONATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2730	ISOBUTYL QUINOLINE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2731	ISOBUTYL SALICYLATE	Е	Only for use in topical medicines for dermal

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			application.
2732	ISOBUTYLENE/ISOPRENE COPOLYMER	E	Only for oral use when the dosage form is chewing gum. The concentration must be consistent with best practice for the production of gum delivery systems.
2733	ISOBUTYRALDEHYDE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2734	ISOBUTYRIC ACID	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2735	ISOCETYL ALCOHOL	E	Only for use in topical medicines for dermal application.
2736	ISOCETYL LINOLEOYL STEARATE	E	Only for use in topical medicines for dermal application.
2737	ISOCETYL STEARATE	E	Only for use in topical medicines for dermal application.
2738	ISOCETYL STEAROYL STEARATE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no more than 10%.
2739	ISOCYCLOCITRAL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			1%.
2740	ISODECYL ISONONANOATE	E	Only for use in topical medicines for dermal application.
2741	ISODECYL NEOPENTANOATE	E	Only for use in topical medicines for dermal application.
2742	ISODECYL OLEATE	E	Only for use in topical medicines for dermal application.
2743	ISODECYL SALICYLATE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no more than 2%.
2744	ISODODECANE	E	Only for use in topical medicines for dermal application.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2745	ISOEICOSANE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no more than 2%.
2746	ISOEUGENOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2747	ISOEUGENYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			medicine must be no more 1%.
2748	ISOEUGENYL BENZYL ETHER	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2749	ISOHEXADECANE	E	Only for use in topical medicines for dermal application.
2750	ISOJASMONE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2751	ISOLEUCINE	A, E	
2752	ISOMALT	Е	When the quantity of sugar alcohols per maximum recommended daily dose is more than 2g, the quantity of

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			the sugar alcohols must be declared on the label and the medicine requires the following warning statement on the medicine label: - (SUGOLS) 'Products containing [insert name of sugar alcohol(s) may have a laxative effect or cause diarrhoea [or words to that effect]'.
2753	ISOMENTHONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2754	ISOMETHYLIONONE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			1%.
2755	ISONONYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used as in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2756	ISONONYL ISONONANOATE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye or on damaged skin. The concentration must be no more than 15%.
2757	ISOPENTANE	E	For dental use only. The concentration must be no more than 2%.
2758	ISOPENTANOIC ACID	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2759	ISOPHORONE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2760	ISOPHYTOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2761	ISOPROPYL 2- METHYLBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2762	ISOPROPYL 4- HYDROXYBENZOATE	E	Only for use in topical medicines for dermal application. Medicines containing hydroxybenzoates require the following warning statement on the medicine label: - (TOTBNZ) 'Contains hydroxybenzoates' (or words to this effect) if the medicine contains more than one hydroxybenzoate source OR 'Contains [insert the approved name of hydroxybenzoate used]' (or words to this effect) if product contains one hydroxybenzoate source.
2763	ISOPROPYL ACETATE	E	Only for use in topical

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			medicines for dermal application.
2764	ISOPROPYL ALCOHOL	E	
2765	ISOPROPYL CAPROATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a
			medicine must be no more than 5%.
2766	ISOPROPYL CINNAMATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour.
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2767	ISOPROPYL ISOSTEARATE	E	Only for use in topical medicines for dermal application.
2768	ISOPROPYL LANOLATE	Е	Only for use in topical medicines for dermal

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			application.
2769	ISOPROPYL LAUROYL SARCOSINATE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no more than 5.6%.
2770	ISOPROPYL MYRISTATE	Е	
2771	ISOPROPYL PALMITATE	Е	Only for use in topical medicines for dermal application.
2772	ISOPROPYL PPG-2 ISODECETH-7 CARBOXYLATE	Е	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no more than 10%.
2773	ISOPROPYL STEARATE	Е	Only for use in topical medicines for dermal application.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2774	ISOPROPYL TITANIUM TRIISOSTEARATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration must be no more than 0.2%.
2775	ISOPROPYL-3-METHYL-BUTANE THIOATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2776	ISOPULEGOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2777	ISORALDEINE 70	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2778	ISOSTEARIC ACID	E	Only for use in topical medicines for dermal application.
2779	ISOSTEAROYL HYDROLYSED COLLAGEN	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration must be no more than 0.3%.
2780	ISOSTEARYL ALCOHOL	Е	Only for use in topical medicines for dermal application.
2781	ISOSTEARYL NEOPENTANOATE	Е	Only for use in topical medicines for dermal application.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2782	ISOSTEARYL PALMITATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration must be no more than 2%.
2783	ISOTRIDECYL ALCOHOL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2784	ISOVALERALDEHYDE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2785	ISOVALERIC ACID	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a
			medicine must be no more than 5%.
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2786	ISPAGHULA HUSK DRY	А, Н	When a dose for children is stated, the medicine requires the following warning statement on the medicine label:
			- (PSYLL) 'On medical advice' (or words to that effect).
2787	ISPAGHULA HUSK POWDER	А, Н	When a dose for children is stated, the medicine requires the following warning statement on the medicine label:
			- (PSYLL) 'On medical advice' (or words to that effect).

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2788	IVA AXILLARIS	A, H	
2789	JAMAICA DOGWOOD BARK DRY	A, H	
2790	JAMAICA DOGWOOD BARK POWDER	A, H	
2791	JASMINE ABSOLUTE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2792	JASMINE LACTONE	E	Only for use in topical medicines for dermal application.
2793	JASMINE OIL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
2794	JASMINUM GRANDIFLORUM	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2795	JASMINUM OFFICINALE	A, E, H	
2796	JASSOLIA	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2797	JATEORHIZA PALMATA	А, Н	
2798	JATROPHA CURCAS	Н	Only for use as an active homoeopathic ingredient
2799	JERUSALEM ARTICHOKE	E	
2800	JOJOBA ESTERS	E	Only for use in topical medicines for dermal application and not to be

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			included in medicines intended for use in the eye. The concentration in the medicine must be no more than 25%.
2801	JUGLANS CINEREA	A, E, H	
2802	JUGLANS NIGRA	A, E, H	
2803	JUGLANS REGIA	A, H	
2804	JUNCUS EFFUSUS	A, H	
2805	JUNIPER BERRY OIL	A, E, H	
2806	JUNIPER BERRY OIL TERPENELESS	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2807	JUNIPERUS CALIFORNICA	A, H	
2808	JUNIPERUS COMMUNIS	A, E, H	
2809	JUNIPERUS MEXICANA	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.

Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

Schedule 1

Table 1 Part 2

Column 1	Column 2	Column 3	Column 4
	Ingredient Name	Purpose of the ingredient in the medicine	Specific requirements(s) applying to the ingredient in Column 2
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2810	JUNIPERUS OXYCEDRUS	A, H	
2811	JUNIPERUS VIRGINIANA	A, E, H	
2812	JUSTICIA ADHATODA	A, H	